BerGenBio ASA (BRRGF) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
BerGenBio ASA has reported progress in its focused approach to develop bemcentinib for first-line treatment in NSCLC patients with STK11 mutations, highlighting the completion of Phase 1b enrollment and ongoing progress of the Phase 2a study. The company has decided to discontinue its tilvestamab activities, while maintaining a healthy financial position with cash reserves of NOK 174.8 million. Investors can expect an interim analysis of the bemcentinib study in early 2025.
For further insights into BRRGF stock, check out TipRanks’ Stock Analysis page.
